Skip to main content
SpringerLink
Log in

Could Pretreatment Pan‑Immune‑Inflammation Value Predict Survival in Esophageal Cancer?

  • Thoracic Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Feng J, Wang L, Yang X, Chen Q, Cheng X. Pretreatment pan-immune-inflammation value (PIV) in predicting therapeutic response and clinical outcomes of neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma. Ann Surg Oncol. 2024;31:272–83.

    Article  PubMed  Google Scholar 

  2. Baba Y, Nakagawa S, Toihata T, et al. Pan-immune-inflammation value and prognosis in patients with esophageal cancer. Ann Surg Open. 2022;3:e113.

    Article  PubMed  Google Scholar 

  3. Song K, Fei S, Li B, Tian J. Application of preoperative pan-immno-inflammatory values in clinicopathological features and prognosis evaluation of esophageal cancer. Mod Dig Interv. 2022;27:834–9.

    Google Scholar 

  4. Feng J, Wang L, Yang X, Chen Q, Cheng X. Clinical utility of preoperative pan-immune-inflammation value (PIV) for prognostication in patients with esophageal squamous cell carcinoma. Int Immunopharmacol. 2023;123:110805.

    Article  CAS  PubMed  Google Scholar 

  5. Qi WX, Wang X, Li C, et al. Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: an analysis from a prospective cohort. Thorac Cancer. 2023;14:1556–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, People’s Republic of China

    Yi Shen MD, Longqi Chen MD & Guowei Che MD

  2. Department of Thoracic Surgery/Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, People’s Republic of China

    Guowei Che MD

Authors
  1. Yi Shen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Longqi Chen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guowei Che MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guowei Che MD.

Ethics declarations

Disclosure

There are no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shen, Y., Chen, L. & Che, G. Could Pretreatment Pan‑Immune‑Inflammation Value Predict Survival in Esophageal Cancer?. Ann Surg Oncol (2024). https://doi.org/10.1245/s10434-024-15100-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1245/s10434-024-15100-7

Search

Navigation